Richard Ridinger succeeds Thomas Leysen, who has retired from the Board. Thomas played a pivotal role in shaping the company’s strategic direction and establishing a strong foundation for its next phase of growth and value creation.
Richard Ridinger has served as an independent member of the Board of Directors of dsm-firmenich since 2023 and, in addition to his role as Chairman, has also been elected as a member of the Compensation Committee. He brings extensive executive and board-level experience across Pharma, Home & Personal Care, and Nutrition & Health, as well as a deep understanding of the company, its strategy and stakeholders.
The Board looks forward to working with Richard Ridinger as dsm-firmenich continues to execute its strategy and create sustainable long-term value for shareholders and other stakeholders. The Board also expresses its sincere gratitude to Thomas for his outstanding leadership and dedication during his tenure.
The detailed voting results of the Extraordinary General Meeting are available on the company’s website.
